Computational evidence
| Protein change | ||
| AlphaMissense | 0.823 | likely pathogenic |
|---|---|---|
| REVEL | 0.928 | moderately pathogenic-leaning |
| SaProt | LLR -5.81 | tolerated |
| ⇒ AlphaMissense and REVEL call this damaging; SaProt does not. | ||
| Splicing | ||
| SpliceAI | — | not assessed · no allele here is in the release |
| Constraint at this position | ||
| Conservation | phyloP 12 | GERP 1.9, phastCons 1 |
| Regional constraint | o/e 0.84 | unconstrained · MANE · 289 kb · p 2e-07 · regional, not allelic |
| Overall | ||
| CADD | 29.7 | PHRED · no single calibrated threshold — expert panels disagree |
AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.
Population frequency
| Ancestry group | Frequency | 1 in |
|---|---|---|
| Remaining individualsnot grpmax-eligible | 0.008% | 12,496 |
| European (non-Finnish)grpmax | 0.00636% | 15,732 |
| Finnishnot grpmax-eligible | 0.00313% | 31,988 |
| East Asian | 0.00223% | 44,882 |
| Admixed American | 0.00167% | 59,976 |
| African / African-American | 0.00134% | 74,872 |
Remaining individuals shows a higher raw frequency than the grpmax group above it. gnomAD excludes bottlenecked groups — Finnish, Ashkenazi Jewish, Amish and “Remaining individuals” — from grpmax, because founder effects make their frequencies unrepresentative for filtering. The table is sorted by frequency, so an excluded group can sit above the grpmax row.
Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.
Variant & gene context
- Gene
- APP
- Protein
- p.Ala713Val
- Coding
- c.2138C>T
- MANE Select
- NM_000484
- dbSNP
- rs1800557
- Type
- single nucleotide variant
- Location
- chr21:25891795 (GRCh38)
- Gene constraint
- LOEUF 0.41 · pLI 1.00 · ClinGen HI 0/3 (gnomAD)
- Structure
- AlphaFold pLDDT 68.11 · 263 PDB
- Residue 713
- a UniProt-annotated variant site (in ad1); a UniProt-annotated variant site (in one chronic schizophrenia patient; uncertain significance); an α-helix; the 'interaction with psen1' region; a functional site (cleavage; by gamma-secretase; site 2)
Similar variants
- APP p.Ala713Thr Likely pathogenic ★★ ⚠ same residue
- APP p.Ala713= Likely benign ★★ same residue
- APP p.Ala713Glu Likely pathogenic ★ same residue
- APP p.Asp694Asn Pathogenic ★★ ⚠ same condition
- APP p.Glu693Gln Pathogenic ★★ ⚠ same condition
- APP p.Ile716Phe Pathogenic ★★ ⚠ same condition
- APP p.Thr714Ala Pathogenic ★★ ⚠ same condition
- APP p.Val715Met Pathogenic/Likely pathogenic ★★ ⚠ same condition
Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →
Cite Sugi Variant
Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/app-p-ala713val (accessed [today's date]).
Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown